.webp)
Our approach to tackling weight loss
We know weight loss is personal and challenging. Our service offers tailored support and tools for lasting results, combining clinically-proven medications with expert advise, guidance and support.
A 2022 study of over 2,500 people found that those using GLP-1/GIP treatment lost up to 20.9% body weight after 72 weeks.
Another weight loss injection you’re probably familiar with is Wegovy. And, while it’s often compared to Mounjaro, there are clear differences between these weight loss medications.
While Mounjaro contains the GLP-1 and GIP hormones, Wegovy mimics just the GLP-1 agonist and as a result, the weight loss outcomes differ between the medications. Mounjaro also tends to have fewer side effects for users when compared to Wegovy.
There are currently no published head-to-head trials directly comparing the weight loss medications, but when looking at the respective clinical trials, patients using GLP-1 and GIP treatment achieved 20.9% body weight loss at 72 weeks versus 14.9% body weight loss at 68 weeks for those on GLP-1 treatment.
Although, it’s important to note that Wegovy still delivers excellent weight loss outcomes, but sits just slightly below Mounjaro in projected weight loss.
To access Mounjaro, you’ll need to undergo a consultation, where one of our GPs can decide which medicine is right for you.
A few of the eligibility requirements of Mounjaro include:
Our clinicians will discuss all the appropriate treatment options and give you a treatment plan to maximise your results.
£200/mo
£225/mo
£250/mo